Informes

Comparación de requisitos de autorización de los medicamentos biológicos y biosimilares

INICIO/Informes | Posted 27/08/2021

El desarrollo de medicamentos biosimilares presupone un cambio de paradigma al modelo tradicional utilizado con un medicamento innovador. Mientras que para una nueva entidad molecular la evidencia de su desarrollo se basa en generar datos que confirmen su seguridad y eficacia.

El uso de biosimilares genera ahorros en el presupuesto sanitario español de 2021

INICIO/Informes | Posted 30/07/2021

Se calcula que el Sistema Nacional de Salud (SNS) podrá ahorrar 930 millones de euros debido al uso de biosimilares en 2021, de acuerdo a los resultados del Análisis de impacto presupuestario de los medicamentos biosimilares en el SNS de España (2009–2022) [1].

Five main barriers to developing biosimilars

INICIO/Informes | Posted 23/07/2021

According to Dr Ash Ramzan, principal consultant at Woodley BioReg, there are five main barriers preventing biosimilars from reaching their full potential.

Posición de la CAEME sobre medicamentos biológicos y biosimilares en Argentina

INICIO/Informes | Posted 02/07/2021

Las compañías farmaceúticas que componen la Cámara Argentina de Especialidades Medicinales (CAEME) consideran que los medicamentos biosimilares son necesarios en pos de la sustentabilidad del sistema de salud y el acceso de los pacientes a un tratamiento efectivo.

A few drugs account for most of Medicare Part B spending

INICIO/Informes | Posted 25/06/2021

Findings from an analysis carried out by KFF of Medicare* spending in 2019 found that most of the Medicare Part B** spending on drugs was on a relatively small number of drugs [1]. KFF is a non-profit organization that provides independent information on national health issues.

Se impulsa un mercado de medicamentos genéricos más amplio y sólido en México

INICIO/Informes | Posted 21/06/2021

En una conferencia de prensa el pasado 14 de noviembre de 2020, se dio a conocer la estrategia “Un nuevo mercado de medicamentos genéricos”, con la que “las secretarías de Salud y de Economía fortalecerán a la industria de la producción de medicamentos genéricos, a través de mecanismos de vinculación y herramientas tecnológicas, con base en los principios de innovación, transparencia, competitividad y legalidad”, impulsando decididamente un mercado de medicamentos genéricos más amplio y sólido, en beneficio de los mexicanos.

A few drugs account for most of Medicare Part D spending

INICIO/Informes | Posted 11/06/2021

An analysis of Medicare* spending in 2019 was recently carried out by KFF, a non-profit organization that provides independent information on national health issues. The analysis found that most of the Medicare Part D** spending on drugs was on a relatively small number of drugs with only one manufacturer and without generic or biosimilar competitors [1].

A small number of drugs account for most of Medicare spending

INICIO/Informes | Posted 04/06/2021

A new analysis carried out by KFF, a non-profit organization that provides independent information on national health issues, has found that a relatively small share of drugs without generic or biosimilar competitors, accounted for a disproportionate share of prescription drug spending in the US Medicare* system in 2019 [1].

Rheumatologists are prescribing more biosimilars

INICIO/Informes | Posted 31/05/2021

Although the use of biosimilars for the treatment of autoimmune diseases varies widely by geographical region, the trend is that rheumatologists are prescribing more biosimilars.

US biosimilars pipeline for growth hormone, infertility and bone health drugs – 2021

INICIO/Informes | Posted 31/05/2021

Global spending on medicine continues to grow. As of 2019, approximately US$1.25 trillion had been spent on medicines, up from just US$887 billion in 2010. That number is expected to increase to US$1.59 billion by 2024, with biologicals making up an increasing part of this total due to their use to treat previously intractable diseases. In fact, spending on biologicals has doubled since 2007 and growth has outstripped that of total sales of pharmaceuticals by a significant margin. The global biologicals market in 2020 was worth approximately US$239.2 billion, and in 2020 five of the top 10 best-selling drugs were biologicals compared with a high of seven in 2018, and only three in 2008 [1].